- Protalix BioTherapeutics Finally Receives FDA Approval To Market Elelyso For Enzyme Replacement Therapy In Gaucher's Disease
- Coronado Biosciences: What Do The Recent Trial Changes Mean For Investors?
- LPath's Form / Fill Delay Disappoints Investors: Long-Term Buying Opportunity?
- Coronado Biosciences: Phase II Trials Provide Multiple Shots On Goal
- Biotech Class Of 2010: IPOs Revisited
Steven Breazzano
Steven Breazzano
Stop FollowingSteven Breazzano
ABOUT
Steven has done extensive work in the field of synthesis of biologically relevant compounds and new organic reaction development – publishing several papers in prestigious peer-reviewed journals. He has been an active stock market investor for the past 5 years and is currently pursuing the Chartered Financial Analyst (CFA) designation (enrolled for level 2, June 2012) as well as a Ph.D. as an NSF predoctoral fellow in synthetic and biological chemistry first at Columbia University (M.A.) and now at The Scripps Research Institute. He focuses primarily on the valuation of smaller biotechs (100MM to 1 BB market cap).
Disclaimer: I make every reasonable effort to make sure all data I present is factual. It is your ...More responsibility to verify any data presented before making an investment decision.
Please visit my website (www.biobip.com) and email me with any questions, comments, and ideas.
Selected publications:
1. Steven P. Breazzano and Dale L. Boger.* Synthesis and Stereochemical Determination of Complestatin A and B (Neuroprotectin A and B). J. Am. Chem. Soc. 2011, ASAP.
2. S. A. Snyder,* N. E. Wright, J. P. Pflueger , S. P. Breazzano. Total Syntheses of Heimiol A, Hopeahainol D, and Constrained Analogues. Angew. Chemie. Int. Ed. 2011, 50, 8629-8633.
3. H. Shimamura, S. P. Breazzano, J. Garfunkle, F. S. Kimball, J. D. Trzupek, D. L. Boger.* Total Synthesis of Complestatin: Development of a Pd(0)-MediatedIndole Annulation for Macrocyclization. J. Am. Chem. Soc. 2010, 132, 7776-7783.
4. S. A. Snyder,* S. P. Breazzano, A. G. Ross, Y. Lin, A. L. Zografos. Total Synthesis of Diverse Carbogenic Complexity within the Resveratrol Class from a Common Building Block, J. Am. Chem. Soc. 2009, 131, 1753-1765.
5. R. Giri, N. Maugel, J.-J. Lie, D.-H. Wang, S. P. Breazzano, L. B. Saunders, J.-Q.Yu.* Palladium-Catalyzed Methylation and Arylation of sp2 and sp3 C-H Bondsin Simple Carboxylic Acids. J. Am. Chem. Soc. 2007, 129, 3510-3511.
6. R. Giri, M. Wasa, S. P. Breazzano, J.-Q. Yu.* Converting gem-Dimethyl Groupsinto Cyclopropanes via Pd-Catalyzed Sequential C-H Activation and RadicalCyclization. Org. Lett. 2006, 8, 5685-5688.
Disclaimer: I make every reasonable effort to make sure all data I present is factual. It is your ...More responsibility to verify any data presented before making an investment decision.
Please visit my website (www.biobip.com) and email me with any questions, comments, and ideas.
Selected publications:
1. Steven P. Breazzano and Dale L. Boger.* Synthesis and Stereochemical Determination of Complestatin A and B (Neuroprotectin A and B). J. Am. Chem. Soc. 2011, ASAP.
2. S. A. Snyder,* N. E. Wright, J. P. Pflueger , S. P. Breazzano. Total Syntheses of Heimiol A, Hopeahainol D, and Constrained Analogues. Angew. Chemie. Int. Ed. 2011, 50, 8629-8633.
3. H. Shimamura, S. P. Breazzano, J. Garfunkle, F. S. Kimball, J. D. Trzupek, D. L. Boger.* Total Synthesis of Complestatin: Development of a Pd(0)-MediatedIndole Annulation for Macrocyclization. J. Am. Chem. Soc. 2010, 132, 7776-7783.
4. S. A. Snyder,* S. P. Breazzano, A. G. Ross, Y. Lin, A. L. Zografos. Total Synthesis of Diverse Carbogenic Complexity within the Resveratrol Class from a Common Building Block, J. Am. Chem. Soc. 2009, 131, 1753-1765.
5. R. Giri, N. Maugel, J.-J. Lie, D.-H. Wang, S. P. Breazzano, L. B. Saunders, J.-Q.Yu.* Palladium-Catalyzed Methylation and Arylation of sp2 and sp3 C-H Bondsin Simple Carboxylic Acids. J. Am. Chem. Soc. 2007, 129, 3510-3511.
6. R. Giri, M. Wasa, S. P. Breazzano, J.-Q. Yu.* Converting gem-Dimethyl Groupsinto Cyclopropanes via Pd-Catalyzed Sequential C-H Activation and RadicalCyclization. Org. Lett. 2006, 8, 5685-5688.
SNAPSHOT
- Description: Doctoral student. Trading frequency: Monthly
- Interests: Options, Stocks - long, Stocks - short
COMPANY
Currently, there is no company profile for Steven Breazzano.
BLOG
The Biotech Investment Paradigm
The Biotech Investment Paradigm covers biopharmaceutical companies with market caps from approximately $50 million to $1 billion. We believe this niche offers tremendously high return and – when handled properly - acceptable risk. It is our goal to assist investors with a portion of the due diligence ...More
necessary to navigate this rewarding, yet challenging, investment landscape. In particular, utilizing our science backgrounds we aim to provide objective, comprehensive coverage analyzing all publicly available information (including patents and scientific publications) and when possible, speak with management teams to create a more complete analysis. We cover publicly traded companies primarily in late clinical stage (so called catalyst-plays, phase III data, NDA, PDUFA, etc.). Occasionally, we will write about earlier stage companies with important upcoming events that we believe merit closer attention.
Book
Currently, there are no book details for Steven Breazzano.
Latest Comments
more »
- Great article, thanks Nicho... on Fifth Street Finance Stock Buyback Unlikely To ...
- Reimbursement is a very big... on Discovery Laboratories: A Hidden Gem In Biotech
- http://bit.ly/LFiXnk It sho... on Amarin: May 16 Patent Updates - What Do They Mean?
- Haha yeah, that patent is b... on Amarin: May 16 Patent Updates - What Do They Mean?
- I think Trius has a fantast... on Bayer And Trius Therapeutics Partnership Is Mov...
Latest comments on Steven's Articles
more »
- trebor 1 on Coronado Biosciences: What Do The Recent Trial ...
- rph1225 on Protalix BioTherapeutics Finally Receives FDA A...
- markking653 on Protalix BioTherapeutics Finally Receives FDA A...
- Steven Breazzano on Protalix BioTherapeutics Finally Receives FDA A...
- Steven Breazzano on Coronado Biosciences: What Do The Recent Trial ...
LATEST ARTICLES & INSTAPOSTS
more »

